Cheapest GLP-1 Medications 2026: Full Cost Comparison

At a glance: cheapest GLP-1 cost comparison (2026)

What this cost comparison covers: the major GLP-1 telehealth brands we have reviewed and the brand-name self-pay programs, 21 options in all. It is not every provider on the market. How it is ranked: by the lowest published monthly price at the starting dose, on any plan length, counting every fee the seller requires. A price that needs a prepaid plan is labelled as such, and the month-to-month price sits next to it. Brand self-pay rows (NovoCare, LillyDirect) are medication only; you also need a prescriber.

Compounded semaglutide and tirzepatide are not FDA-approved, have not been evaluated by the FDA for safety, effectiveness or quality, and are not therapeutically equivalent to Wegovy, Ozempic, Zepbound or Mounjaro. Microdose plans (Henry Meds, Noom) are priced separately and left out because they are not a standard starting dose. Prices change often; the seller's checkout is the final word.

Sticker price vs. all-in cost: why the cheapest headline isn't always the cheapest program

Three things move the real number:

• Plan length. The lowest prices need prepayment: Cora's $99 is $1,188 upfront, Ro's $74 membership is $888 upfront. Check the refund terms before you prepay.
• A separate membership fee. Ivim, Mochi, Ro, Hims, Hers and LifeMD charge a membership on top of the medication. The table adds them together.
• Dose steps. Most prices rise as doses increase. Cora's do not; the brand pills roughly double from the starting dose to the top dose.

Coaching and nutrition guidance can help, since the drugs are meant to be used alongside dietary and lifestyle changes. But when comparing programs, get one number: medication + membership + visit, at your likely dose, for the months you will actually stay. Our GLP-1 cost guide for 2026 and the compounded vs. brand GLP-1: a cost comparison go deeper; drug-by-drug, see semaglutide cost and tirzepatide cost without insurance.

The compounded reality

Every compounded option in the table is cheaper than its brand-name counterpart, and every one is not FDA-approved. Here is what that means, with the FDA's own pages linked.

• Not reviewed the way approved drugs are. The FDA does not review compounded drugs for safety, effectiveness or quality before they are sold, and it has received reports of dosing errors and adverse events with compounded GLP-1s (FDA's concerns with unapproved GLP-1 drugs). The doctors who prescribe it are licensed; the drug itself is not approved.
• 503A vs. 503B. A 503A pharmacy is state-licensed and compounds for an individual patient's prescription. A 503B outsourcing facility registers with the FDA, follows federal manufacturing standards (CGMP), and can make larger batches (FDA compounding Q&A).
• Why it costs less. Compounders skip the clinical trials, brand marketing and patent pricing behind Wegovy and Zepbound; they buy the active ingredient and mix it. The lower price reflects that, not equal evidence.
• What changed when the shortages ended. The FDA declared the tirzepatide shortage over in December 2024 and semaglutide's in February 2025, then ended the grace periods for mass compounding in 2025 (FDA: Policies for compounders as GLP-1 supply stabilizes). Copies of the approved drugs are no longer allowed; a 503A pharmacy may still compound for an individual patient's documented clinical need. In May 2026 the FDA proposed excluding both molecules from 503B bulk compounding (Federal Register, May 1, 2026); as of Oct 10, 2026 it is not final.

Compounded semaglutide and tirzepatide are available through every compounded provider in the table, but they are not the same products as Wegovy or Zepbound. If you want the approved drug, the brand rows are FDA-approved branded drugs, not compounded versions; you can also buy Zepbound vials directly through LillyDirect.

Is cheap always safe? How to evaluate a provider

Before you pay, ask these questions and get written answers:

• Which pharmacy fills it? You want a named and verifiable state-licensed 503A compounding pharmacy (or an FDA-registered 503B facility) you can look up. TrimRx, for one, does not name its pharmacy.
• Is the pharmacy licensed in my state? Check your state board of pharmacy.
• Which salt form? The FDA has warned against salt forms such as semaglutide sodium or acetate, which differ from the approved base.
• What is the all-in monthly charge at my dose, and what are the refund and cancellation terms? Billing and refunds are the top complaint themes in our reviews.
• Does a clinician actually review me? A legitimate program checks clinical eligibility criteria and medical history before prescribing.

Avoid anyone who ships without a prescription, sells "research use only" vials, or says a compounded product is FDA-approved or the same as a brand drug. For more side-by-side detail, see the ranked comparison of compounded GLP-1 telehealth providers and, for tirzepatide, the cheapest compounded tirzepatide online.

Brand self-pay options in 2026: what each drug costs

Every price here is the manufacturer's own self-pay price, checked Oct 10, 2026. You still need a prescription, and the visit is billed separately.

• Wegovy pill: $149/mo at 1.5 mg, $199 at 4 mg, $299 at 9 and 25 mg (NovoCare's Wegovy cost page).
• Wegovy pen: $349/mo from 0.25 to 2.4 mg; new patients pay $199 for their first two fills through Dec 31, 2026.
• Foundayo (orforglipron): the first oral GLP-1 for weight that needs no food or water timing, FDA-approved on April 1, 2026; $149/mo at 0.8 mg through LillyDirect; $299 at 9 mg and up if refilled within 45 days, $349 otherwise at the top doses (checked Oct 13, 2026).
• Zepbound: $299/mo at 2.5 mg, $399 at 5 mg and $449 at higher doses if refilled within 45 days, through LillyDirect.
• Ozempic and Mounjaro are approved for type 2 diabetes. Ozempic's self-pay pen is $349/mo at 0.25–1 mg; Mounjaro's single-dose pen is $499/mo at every dose through LillyDirect (checked Oct 13, 2026).

Drug-by-drug guides: Ozempic cost without insurance, Wegovy cost without insurance and Zepbound cost without insurance.

Manufacturer savings cards and patient assistance: the real $0–$25 floor

If your commercial insurance covers a GLP-1, NovoCare and LillyDirect savings cards can bring your cost down to about $25/mo (not usable with Medicare or Medicaid). If you are uninsured or underinsured and meet income limits, Novo Nordisk and Lilly patient-assistance programs can supply the drug at no cost. Either one beats every cash price in the table, so check them first.

Medicare and coverage options in 2026

The Medicare GLP-1 Bridge (July 1, 2026 to Dec 31, 2027) gives eligible Part D members a flat $50/mo for Wegovy, the Zepbound KwikPen or Foundayo; see the CMS Medicare GLP-1 Bridge page. Many commercial plans still exclude weight-loss GLP-1s; see does insurance cover Wegovy and Zepbound? and how to get a GLP-1 covered by insurance. Paying cash? See using HSA/FSA for a GLP-1.

Compare published GLP-1 prices →

Frequently asked questions

What's the cheapest GLP-1 without insurance?

In our comparison, the lowest published price at the starting dose is compounded semaglutide from Cora at $99/mo on a 12-month prepaid plan ($175 month-to-month); the lowest FDA-approved options are the Wegovy pill and Foundayo at $149/mo, medication only. Compounded GLP-1s are not FDA-approved.

What's the cheapest way to get semaglutide online?

Among the providers we compared, compounded semaglutide starts at $99/mo on a prepaid annual plan (Cora) or $109/mo with Mochi Health, which is not FDA-approved; the FDA-approved Wegovy pill is $149/mo at 1.5 mg through NovoCare, plus a prescriber visit.

Which GLP-1 is cheapest — Ozempic, Wegovy, Zepbound, or compounded?

At self-pay starting doses: the Wegovy pill is $149/mo, Zepbound vials $299/mo, and the Wegovy and Ozempic pens $349/mo after a $199 intro, while compounded semaglutide and tirzepatide start lower ($99–$150/mo in our table) but are not FDA-approved.

Is it safe to buy a GLP-1 online?

It can be, from a licensed telehealth provider that requires a clinician visit and names the state-licensed pharmacy that fills it. The FDA warns about counterfeit and unapproved GLP-1s sold online, so avoid anyone who ships without a prescription or calls a compounded drug FDA-approved.

Does FSA or HSA cover compounded GLP-1?

Often, when it is prescribed to treat a medical condition, since that can be a qualified medical expense; check with your plan administrator first.

How low will GLP-1 prices go in 2026?

Brand self-pay prices now start at $149/mo for the pills, and Medicare's GLP-1 Bridge charges eligible Part D members $50/mo through Dec 31, 2027. No U.S. generic semaglutide or tirzepatide is expected before patents expire in the early 2030s.

What is the cheapest GLP-1 pill?

Foundayo (0.8 mg) and the Wegovy pill (1.5 mg) both start at $149/mo self-pay, and both rise at higher doses. Compounded tablets are sometimes cheaper but are not FDA-approved.

What BMI do I need to qualify for a GLP-1?

Generally a BMI of 30 or more, or 27 or more with a weight-related condition such as high blood pressure. A licensed clinician makes the call.

Is compounded semaglutide still legal in 2026?

Yes, but narrowly: since the shortage ended in February 2025, a state-licensed 503A pharmacy may compound it for an individual patient's documented need, not as a copy of Wegovy. It is not FDA-approved.

How much is Ozempic with a GoodRx coupon or at Costco?

Ozempic's self-pay price through NovoCare is $349/mo at 0.25–1 mg (new patients $199 for two fills); coupon and warehouse prices vary by pharmacy, so compare a few before filling.

Who qualifies for the $50 Medicare GLP-1 Bridge?

Part D members aged 18 or older who meet BMI criteria (roughly 35+, or lower with certain heart or metabolic conditions), through Dec 31, 2027. It covers Wegovy, the Zepbound KwikPen and Foundayo.

What should I do if my insurance denies a GLP-1?

Ask your prescriber for a letter of medical necessity, then file an internal appeal and, if needed, an external review. Self-pay brand programs are the fallback.

The bottom line

In our comparison, the lowest published price at the starting dose is Cora's compounded semaglutide at $99/mo on an annual plan ($175 month-to-month), and the lowest FDA-approved prices are the Wegovy pill and Foundayo at $149/mo. If you have insurance or Medicare, a savings card or the $50 Bridge may cost less than anything here. Whatever you choose, compare the all-in monthly price at your likely dose, the plan length you are committing to, and the pharmacy behind it. See what licensed providers charge.

Sources & references

• Provider prices: each seller's own site, linked in the table, checked Oct 9–10, 2026.
• FDA: Human Drug Compounding
• FDA: Postmarket Drug Safety — GLP-1 unapproved product concerns
• FDA: Policies for compounders as GLP-1 supply stabilizes
• FDA: Proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk-substance list (proposed May 2026)
• NIDDK: Prescription medications to treat overweight and obesity
• CMS: Medicare GLP-1 Bridge — $50/month program (launched July 1, 2026).
• Wegovy self-pay pricing — NovoCare (checked Oct 10, 2026).
• Zepbound self-pay vials — LillyDirect (checked Oct 10, 2026).
• Eli Lilly: FDA approves Foundayo (orforglipron), oral GLP-1 pill for weight management (April 1, 2026).
• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM, 2021.
• Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM, 2022.
• Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM, 2023.

Compounded semaglutide and tirzepatide are not FDA-approved, have not been evaluated by the FDA for safety, effectiveness or quality, and are not therapeutically equivalent to Wegovy, Ozempic, Zepbound or Mounjaro. Not medical advice. Nouri is a publisher; it does not prescribe or sell any medication.

Disclosure: Nouri may earn a commission when you sign up with some of the providers we link to. It doesn't change what you pay or how we rank providers. Every position in the table follows the method above. Full disclosure.